{
    "clinical_study": {
        "@rank": "31618", 
        "acronym": "INTENSE-HF", 
        "arm_group": [
            {
                "arm_group_label": "telemonitoring", 
                "arm_group_type": "Other", 
                "description": "patients in the telemonitoring arm will record vital parameters (blood pressure, heart rate, body weight) and transmit these parameters together with wellbeing and daily dose of heart failure medication"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "Other", 
                "description": "patients in the control arm will not record any vital parameter"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to test a new medical device for optimizing treatment of heart\n      failure and compare its effect on outcome of patients with a recent hospitalization for\n      worsening heart failure"
        }, 
        "brief_title": "Integrated Telemonitoring and Nurse Support Evaluation", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "Patients after an episode of acute heart failure have an increased risk of rehospitalisation\n      and impaired prognosis for survival. Neither a sole mobile nurse support nor a sole\n      telemonitoring system has been able to provide consistent data on a beneficial influence on\n      prognosis. Furthermore, the influence of frequent measurements of NT-pro-BNP in a home\n      setting of heart failure patients has not been investigated so far.\n\n      This study will test a new medical device (software) for optimizing treatment of heart\n      failure patients and evaluate its impact on outcome of these patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  acute systolic heart failure with admission for at least 4 consecutive days\n\n          -  treatment with an ACE-inhibitor/angiotensin receptor blocker, beta-blocker,\n             mineralocorticoid receptor antagonist according to current ESC-guidelines\n\n          -  treatment with a loop diuretic\n\n          -  stable renal function (eGFR according to MDRD of at least 30ml)\n\n          -  written informed consent\n\n          -  minimum age of 18 years\n\n        Exclusion Criteria:\n\n          -  unstable coronary artery disease with revascularisation of any type within the last\n             two months\n\n          -  planned revascularisation or operation for valvular heart disease within the next 6\n             months\n\n          -  planned heart transplantation\n\n          -  uncontrolled hypertension\n\n          -  active myocarditis\n\n          -  malignant disease with a life expectancy of less than 18 months\n\n          -  chronic use of high-dose NSAID or COX-2-inhibitors\n\n          -  psychiatric disorders that make it unlikely to understand the protocol\n\n          -  participation in an other randomized trial\n\n          -  inability to operate a smartphone"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01700218", 
            "org_study_id": "24-537 ex 11/12"
        }, 
        "intervention": [
            {
                "arm_group_label": "telemonitoring", 
                "intervention_name": "telemonitoring", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "control", 
                "intervention_name": "control", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "telemonitoring", 
        "lastchanged_date": "October 28, 2013", 
        "link": {
            "description": "website of the Ludwig Boltzmann Institute for translational heart failure research", 
            "url": "http://heart.lbg.ac.at"
        }, 
        "location": {
            "contact": {
                "email": "friedrich.fruhwald@medunigraz.at", 
                "last_name": "Friedrich M Fruhwald, MD", 
                "phone": "+43-316-385", 
                "phone_ext": "12544"
            }, 
            "contact_backup": {
                "email": "daniel.scherr@medunigraz.at", 
                "last_name": "Daniel Scherr, MD", 
                "phone": "+43-316-385", 
                "phone_ext": "12544"
            }, 
            "facility": {
                "address": {
                    "city": "Graz", 
                    "country": "Austria", 
                    "zip": "8036"
                }, 
                "name": "Medical University"
            }, 
            "investigator": [
                {
                    "last_name": "Friedrich M Fruhwald, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Daniel Scherr, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "Integrated Telemonitoring and Nurse Support Evaluation in Heart Failure", 
        "other_outcome": {
            "description": "The exploratory endpoint will focus on the percentage of optimal dosing (according to current ESC-guidelines) for ACE-inhibitors, angiotensin receptor blockers and beta-blockers", 
            "measure": "exploratory endpoint", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "overall_contact": {
            "email": "friedrich.fruhwald@medunigraz.at", 
            "last_name": "Friedrich M Fruhwald, MD", 
            "phone": "+43-316-385", 
            "phone_ext": "12544"
        }, 
        "overall_contact_backup": {
            "email": "daniel.scherr@medunigraz.at", 
            "last_name": "Daniel Scherr, MD", 
            "phone": "+43-316-385", 
            "phone_ext": "12544"
        }, 
        "overall_official": {
            "affiliation": "Medical University of Graz", 
            "last_name": "Friedrich M Fruhwald, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Austrian Medicines and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "outcome assessment will be done by a blinded committee", 
            "measure": "all cause mortality and hospitalization for worsening heart failure", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01700218"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "days alive and out of hospital", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Medical University of Graz", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ludwig Boltzmann Institute for translational heart failure research", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "AIT Austrian Institute of Technology GmbH", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Medical University of Graz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}